patient_id stringlengths 12 12 | record_id stringlengths 11 11 | cancer_type stringclasses 1
value | histology stringclasses 3
values | stage_at_diagnosis stringclasses 3
values | driver_mutation stringclasses 7
values | pd_l1_tps_percent int64 5 41 | tmb_mutations_per_mb float64 1.5 25 | age_at_diagnosis int64 38 90 | sex stringclasses 2
values | ecog_performance_status int64 0 4 | smoking_pack_years int64 0 111 | primary_tumor_size_cm float64 2 10 | metastatic_sites_count int64 0 11 | first_line_regimen stringclasses 6
values | overall_survival_months float64 4 83 | censored bool 2
classes | msi_status stringclasses 2
values | record_generation_timestamp stringdate 2026-03-15 05:35:56 2026-03-15 05:36:02 | synthetic_source stringclasses 1
value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ANODE_321530 | REC_0014801 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 27 | 15.9 | 87 | female | 2 | 7 | 6.3 | 1 | osimertinib 80 mg daily | 30.6 | false | MSI-H | 2026-03-15T05:36:00.926482+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_629471 | REC_0014802 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 23 | 4.5 | 57 | male | 0 | 17 | 6.5 | 1 | carboplatin + paclitaxel + pembrolizumab | 21.8 | true | MSS | 2026-03-15T05:36:00.926839+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_316195 | REC_0014803 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 25 | 6.6 | 73 | male | 2 | 45 | 5.6 | 6 | carboplatin + paclitaxel + pembrolizumab | 11.3 | false | MSS | 2026-03-15T05:36:00.927207+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_963444 | REC_0014804 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 23 | 8.6 | 62 | female | 1 | 22 | 5.4 | 1 | osimertinib 80 mg daily | 13.8 | true | MSS | 2026-03-15T05:36:00.927558+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_291555 | REC_0014805 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 29 | 13.5 | 73 | female | 1 | 11 | 5.5 | 2 | entrectinib 600 mg daily | 24.5 | true | MSI-H | 2026-03-15T05:36:00.927900+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_915400 | REC_0014806 | Non-small cell lung cancer | Adenocarcinoma | III | KRAS G12C | 24 | 5 | 69 | female | 1 | 8 | 6 | 0 | sotorasib 960 mg daily | 59.5 | false | MSS | 2026-03-15T05:36:00.928268+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_898023 | REC_0014807 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 21 | 5.7 | 68 | female | 1 | 14 | 6.6 | 5 | carboplatin + paclitaxel + pembrolizumab | 13.1 | true | MSS | 2026-03-15T05:36:00.928593+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_892158 | REC_0014808 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 17 | 12.7 | 62 | male | 1 | 12 | 7 | 5 | osimertinib 80 mg daily | 17.9 | true | MSI-H | 2026-03-15T05:36:00.929096+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_125843 | REC_0014809 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 25 | 8.5 | 77 | female | 0 | 17 | 6.1 | 7 | osimertinib 80 mg daily | 14.1 | false | MSS | 2026-03-15T05:36:00.929476+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_855695 | REC_0014810 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 25 | 14.8 | 63 | male | 0 | 20 | 5.4 | 7 | entrectinib 600 mg daily | 8.4 | false | MSS | 2026-03-15T05:36:00.929831+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_101235 | REC_0014811 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 27 | 13 | 73 | male | 1 | 14 | 5.4 | 8 | alectinib 600 mg BID | 8.4 | true | MSI-H | 2026-03-15T05:36:00.930204+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_192707 | REC_0014812 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 24 | 12.4 | 88 | female | 2 | 8 | 5.7 | 2 | entrectinib 600 mg daily | 16.7 | true | MSI-H | 2026-03-15T05:36:00.930554+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_597060 | REC_0014813 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 25 | 8.3 | 70 | female | 0 | 60 | 5.2 | 7 | pembrolizumab 200 mg q3w | 11.8 | false | MSS | 2026-03-15T05:36:00.930900+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_772715 | REC_0014814 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 24 | 5.9 | 71 | female | 1 | 9 | 6.8 | 5 | osimertinib 80 mg daily | 11.4 | true | MSS | 2026-03-15T05:36:00.931219+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_571901 | REC_0014815 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 23 | 7.1 | 60 | male | 0 | 28 | 6 | 5 | sotorasib 960 mg daily | 10.3 | false | MSS | 2026-03-15T05:36:00.931554+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_841042 | REC_0014816 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 24 | 10.6 | 67 | female | 1 | 11 | 5.6 | 5 | osimertinib 80 mg daily | 10.8 | false | MSI-H | 2026-03-15T05:36:00.931909+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_644017 | REC_0014817 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 24 | 18 | 63 | male | 1 | 8 | 4.8 | 6 | osimertinib 80 mg daily | 13.1 | false | MSI-H | 2026-03-15T05:36:00.932393+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_911229 | REC_0014818 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 29 | 13 | 58 | male | 0 | 14 | 6 | 1 | entrectinib 600 mg daily | 17 | false | MSS | 2026-03-15T05:36:00.932802+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_536336 | REC_0014819 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 22 | 8.2 | 75 | female | 1 | 75 | 6.2 | 1 | carboplatin + paclitaxel + pembrolizumab | 14.8 | false | MSS | 2026-03-15T05:36:00.933148+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_887761 | REC_0014820 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 19 | 9.9 | 87 | female | 1 | 20 | 6.1 | 2 | entrectinib 600 mg daily | 22.3 | true | MSS | 2026-03-15T05:36:00.933490+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_860628 | REC_0014821 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 34 | 16.9 | 61 | male | 1 | 23 | 5.8 | 5 | sotorasib 960 mg daily | 12.8 | false | MSS | 2026-03-15T05:36:00.933993+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_356343 | REC_0014822 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 21 | 14.1 | 77 | male | 3 | 23 | 6.1 | 3 | osimertinib 80 mg daily | 13.4 | true | MSI-H | 2026-03-15T05:36:00.934419+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_279081 | REC_0014823 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 26 | 14.1 | 50 | female | 0 | 9 | 4.6 | 6 | osimertinib 80 mg daily | 8 | false | MSI-H | 2026-03-15T05:36:00.934824+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_375731 | REC_0014824 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 12 | 3.1 | 70 | female | 1 | 21 | 5.9 | 7 | carboplatin + paclitaxel + pembrolizumab | 7.8 | false | MSS | 2026-03-15T05:36:00.935244+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_731395 | REC_0014825 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 23 | 17.1 | 50 | male | 0 | 7 | 5.8 | 1 | osimertinib 80 mg daily | 20.4 | true | MSS | 2026-03-15T05:36:00.935645+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_209151 | REC_0014826 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 23 | 12.2 | 59 | male | 1 | 17 | 5.4 | 6 | osimertinib 80 mg daily | 5.9 | false | MSI-H | 2026-03-15T05:36:00.936156+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_282192 | REC_0014827 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 25 | 10.5 | 84 | female | 3 | 18 | 7.1 | 6 | osimertinib 80 mg daily | 13.5 | false | MSS | 2026-03-15T05:36:00.936782+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_685759 | REC_0014828 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 23 | 6.1 | 65 | male | 0 | 17 | 3 | 6 | pembrolizumab 200 mg q3w | 16.8 | false | MSS | 2026-03-15T05:36:00.937220+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_404221 | REC_0014829 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 12 | 11.7 | 77 | female | 1 | 24 | 3.4 | 3 | osimertinib 80 mg daily | 14.1 | true | MSI-H | 2026-03-15T05:36:00.937561+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_248629 | REC_0014830 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 26 | 9.5 | 66 | female | 0 | 33 | 5.8 | 6 | carboplatin + paclitaxel + pembrolizumab | 12.4 | true | MSS | 2026-03-15T05:36:00.937898+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_806493 | REC_0014831 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 24 | 19.4 | 62 | male | 0 | 13 | 4.2 | 7 | alectinib 600 mg BID | 12.9 | false | MSS | 2026-03-15T05:36:00.938238+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_176408 | REC_0014832 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 19 | 3.9 | 76 | male | 2 | 53 | 6.3 | 5 | carboplatin + paclitaxel + pembrolizumab | 6.8 | true | MSS | 2026-03-15T05:36:00.938567+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_149611 | REC_0014833 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 23 | 11.8 | 63 | female | 0 | 4 | 4.3 | 9 | sotorasib 960 mg daily | 16.1 | true | MSS | 2026-03-15T05:36:00.938897+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_414186 | REC_0014834 | Non-small cell lung cancer | Adenocarcinoma | III | ALK fusion | 29 | 11.9 | 67 | female | 0 | 14 | 3.5 | 0 | alectinib 600 mg BID | 58.7 | true | MSI-H | 2026-03-15T05:36:00.939413+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_259295 | REC_0014835 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 15 | 3.6 | 63 | female | 0 | 24 | 4.7 | 9 | carboplatin + paclitaxel + pembrolizumab | 12.9 | false | MSS | 2026-03-15T05:36:00.939805+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_476833 | REC_0014836 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 25 | 11.9 | 73 | female | 2 | 5 | 7 | 1 | sotorasib 960 mg daily | 12.2 | false | MSS | 2026-03-15T05:36:00.940218+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_280972 | REC_0014837 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 19 | 6.4 | 48 | female | 0 | 37 | 6.3 | 6 | carboplatin + paclitaxel + pembrolizumab | 10.7 | true | MSS | 2026-03-15T05:36:00.940576+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_702529 | REC_0014838 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 27 | 4.5 | 59 | female | 0 | 16 | 5 | 2 | pembrolizumab 200 mg q3w | 23 | false | MSS | 2026-03-15T05:36:00.940904+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_440553 | REC_0014839 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 26 | 8.6 | 66 | female | 1 | 14 | 6 | 6 | sotorasib 960 mg daily | 12.4 | false | MSS | 2026-03-15T05:36:00.941239+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_421337 | REC_0014840 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 21 | 10.9 | 50 | male | 0 | 21 | 7.3 | 2 | osimertinib 80 mg daily | 14.8 | true | MSS | 2026-03-15T05:36:00.941570+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_393634 | REC_0014841 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 29 | 10.1 | 73 | female | 2 | 15 | 5.3 | 1 | sotorasib 960 mg daily | 9.9 | false | MSS | 2026-03-15T05:36:00.941881+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_327112 | REC_0014842 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 15 | 5.9 | 70 | female | 2 | 31 | 3.8 | 5 | carboplatin + paclitaxel + pembrolizumab | 11.5 | true | MSS | 2026-03-15T05:36:00.942192+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_344513 | REC_0014843 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 27 | 14.2 | 58 | male | 1 | 22 | 4.7 | 2 | osimertinib 80 mg daily | 25.2 | false | MSS | 2026-03-15T05:36:00.942532+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_285695 | REC_0014844 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 21 | 3.9 | 70 | female | 2 | 12 | 3.8 | 4 | sotorasib 960 mg daily | 13.2 | true | MSS | 2026-03-15T05:36:00.942871+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_893042 | REC_0014845 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 25 | 9.4 | 75 | female | 1 | 12 | 5.1 | 1 | entrectinib 600 mg daily | 19.6 | false | MSS | 2026-03-15T05:36:00.943221+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_300599 | REC_0014846 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 25 | 14.8 | 56 | male | 1 | 20 | 5 | 4 | osimertinib 80 mg daily | 9.6 | true | MSS | 2026-03-15T05:36:00.943576+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_860232 | REC_0014847 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 22 | 5.1 | 67 | female | 0 | 19 | 4.9 | 5 | entrectinib 600 mg daily | 10.2 | false | MSS | 2026-03-15T05:36:00.944122+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_324313 | REC_0014848 | Non-small cell lung cancer | Adenocarcinoma | III | KRAS G12C | 27 | 12 | 86 | female | 1 | 4 | 6.2 | 0 | sotorasib 960 mg daily | 6.5 | true | MSS | 2026-03-15T05:36:00.944493+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_221323 | REC_0014849 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 28 | 12.7 | 77 | female | 2 | 9 | 4.7 | 7 | entrectinib 600 mg daily | 7.2 | true | MSS | 2026-03-15T05:36:00.944816+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_244359 | REC_0014850 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 25 | 8.2 | 65 | female | 0 | 61 | 6.5 | 6 | carboplatin + paclitaxel + pembrolizumab | 8.7 | false | MSS | 2026-03-15T05:36:00.945134+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_605333 | REC_0014851 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 25 | 11.7 | 70 | male | 1 | 12 | 7.5 | 6 | alectinib 600 mg BID | 11.6 | false | MSS | 2026-03-15T05:36:00.945452+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_992387 | REC_0014852 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 25 | 11.1 | 67 | male | 1 | 11 | 6.1 | 4 | sotorasib 960 mg daily | 14.6 | false | MSI-H | 2026-03-15T05:36:00.945777+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_256769 | REC_0014853 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 31 | 5.7 | 59 | female | 1 | 47 | 5.5 | 1 | carboplatin + paclitaxel + pembrolizumab | 6.6 | false | MSS | 2026-03-15T05:36:00.946079+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_937083 | REC_0014854 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 21 | 14.6 | 69 | female | 1 | 21 | 4 | 2 | alectinib 600 mg BID | 29.8 | false | MSI-H | 2026-03-15T05:36:00.946365+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_926162 | REC_0014855 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 20 | 6 | 69 | female | 1 | 33 | 5.9 | 2 | carboplatin + paclitaxel + pembrolizumab | 20.9 | false | MSS | 2026-03-15T05:36:00.946652+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_646367 | REC_0014856 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 33 | 8.2 | 64 | male | 0 | 25 | 5.8 | 4 | carboplatin + paclitaxel + pembrolizumab | 13.4 | false | MSS | 2026-03-15T05:36:00.946947+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_547626 | REC_0014857 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 21 | 14.2 | 75 | female | 2 | 20 | 6.2 | 7 | osimertinib 80 mg daily | 6.5 | true | MSS | 2026-03-15T05:36:00.947249+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_627341 | REC_0014858 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 22 | 11 | 64 | male | 1 | 48 | 6 | 2 | carboplatin + paclitaxel + pembrolizumab | 12.1 | false | MSI-H | 2026-03-15T05:36:00.947553+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_758407 | REC_0014859 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 27 | 5.8 | 66 | female | 0 | 34 | 5.2 | 2 | carboplatin + paclitaxel + pembrolizumab | 19.9 | true | MSS | 2026-03-15T05:36:00.947827+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_367246 | REC_0014860 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 24 | 15.7 | 73 | female | 2 | 27 | 10 | 1 | osimertinib 80 mg daily | 9.2 | true | MSS | 2026-03-15T05:36:00.948338+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_955629 | REC_0014861 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 22 | 18.8 | 55 | female | 1 | 10 | 7 | 6 | alectinib 600 mg BID | 4.7 | false | MSI-H | 2026-03-15T05:36:00.948684+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_153981 | REC_0014862 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 23 | 18.1 | 78 | female | 0 | 1 | 5.6 | 7 | osimertinib 80 mg daily | 13 | false | MSS | 2026-03-15T05:36:00.948999+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_978227 | REC_0014863 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 26 | 16.5 | 78 | female | 1 | 9 | 4.1 | 4 | entrectinib 600 mg daily | 7.8 | false | MSS | 2026-03-15T05:36:00.949330+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_262263 | REC_0014864 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 25 | 11.2 | 60 | female | 1 | 11 | 6.1 | 6 | osimertinib 80 mg daily | 19.4 | false | MSI-H | 2026-03-15T05:36:00.949649+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_310393 | REC_0014865 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 24 | 11.4 | 74 | female | 1 | 32 | 3.6 | 1 | sotorasib 960 mg daily | 14.8 | false | MSS | 2026-03-15T05:36:00.949959+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_843029 | REC_0014866 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 24 | 13.8 | 70 | female | 1 | 23 | 5.8 | 7 | entrectinib 600 mg daily | 10.7 | true | MSS | 2026-03-15T05:36:00.950290+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_304443 | REC_0014867 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 21 | 14.8 | 52 | male | 0 | 25 | 5.3 | 6 | sotorasib 960 mg daily | 9.2 | true | MSI-H | 2026-03-15T05:36:00.950632+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_636108 | REC_0014868 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 27 | 6.1 | 51 | male | 0 | 31 | 2.7 | 2 | carboplatin + paclitaxel + pembrolizumab | 17.7 | false | MSS | 2026-03-15T05:36:00.950976+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_650173 | REC_0014869 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 29 | 13.2 | 65 | female | 1 | 2 | 4.1 | 1 | osimertinib 80 mg daily | 12.3 | false | MSI-H | 2026-03-15T05:36:00.951323+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_613900 | REC_0014870 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 24 | 8.9 | 66 | female | 1 | 0 | 5 | 7 | osimertinib 80 mg daily | 8.6 | true | MSS | 2026-03-15T05:36:00.951645+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_786752 | REC_0014871 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 26 | 11 | 61 | female | 1 | 7 | 7.1 | 1 | osimertinib 80 mg daily | 17.6 | true | MSI-H | 2026-03-15T05:36:00.952001+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_796443 | REC_0014872 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 28 | 12.7 | 80 | female | 1 | 17 | 5.5 | 4 | osimertinib 80 mg daily | 9.8 | false | MSS | 2026-03-15T05:36:00.952395+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_967286 | REC_0014873 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 27 | 5.3 | 67 | female | 0 | 67 | 6.7 | 1 | carboplatin + paclitaxel + pembrolizumab | 29.6 | true | MSS | 2026-03-15T05:36:00.952883+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_203737 | REC_0014874 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 29 | 19.2 | 55 | male | 1 | 21 | 6.3 | 6 | sotorasib 960 mg daily | 15.3 | false | MSI-H | 2026-03-15T05:36:00.953266+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_603322 | REC_0014875 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 24 | 15.9 | 67 | female | 0 | 3 | 5.9 | 1 | osimertinib 80 mg daily | 19.1 | false | MSS | 2026-03-15T05:36:00.953608+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_248832 | REC_0014876 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 23 | 7.2 | 67 | female | 0 | 28 | 5.6 | 1 | carboplatin + paclitaxel + pembrolizumab | 18.6 | false | MSS | 2026-03-15T05:36:00.953911+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_311117 | REC_0014877 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 16 | 15.3 | 64 | male | 0 | 19 | 6.3 | 8 | osimertinib 80 mg daily | 9.7 | true | MSI-H | 2026-03-15T05:36:00.954227+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_998010 | REC_0014878 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 27 | 16.1 | 72 | female | 2 | 21 | 3.9 | 7 | alectinib 600 mg BID | 12.8 | false | MSS | 2026-03-15T05:36:00.954532+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_684556 | REC_0014879 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 33 | 5.9 | 65 | male | 0 | 12 | 4.6 | 1 | sotorasib 960 mg daily | 22.9 | false | MSS | 2026-03-15T05:36:00.954850+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_172843 | REC_0014880 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 27 | 15.8 | 76 | male | 0 | 21 | 4.6 | 4 | osimertinib 80 mg daily | 9.3 | true | MSS | 2026-03-15T05:36:00.955171+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_584983 | REC_0014881 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 30 | 14.8 | 67 | female | 0 | 10 | 6.2 | 5 | alectinib 600 mg BID | 16.1 | true | MSS | 2026-03-15T05:36:00.955491+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_529420 | REC_0014882 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 24 | 16.4 | 57 | male | 1 | 22 | 5.3 | 1 | entrectinib 600 mg daily | 30.5 | false | MSI-H | 2026-03-15T05:36:00.955804+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_506786 | REC_0014883 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 25 | 17.9 | 62 | female | 0 | 10 | 6.8 | 5 | entrectinib 600 mg daily | 13.5 | false | MSI-H | 2026-03-15T05:36:00.956258+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_332412 | REC_0014884 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 21 | 3.7 | 69 | male | 1 | 44 | 6.9 | 6 | carboplatin + paclitaxel + pembrolizumab | 7.5 | false | MSS | 2026-03-15T05:36:00.956625+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_383973 | REC_0014885 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 25 | 14.8 | 76 | female | 1 | 16 | 6.5 | 7 | entrectinib 600 mg daily | 14.8 | false | MSI-H | 2026-03-15T05:36:00.956933+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_311561 | REC_0014886 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 30 | 8.5 | 67 | female | 1 | 36 | 5.7 | 6 | carboplatin + paclitaxel + pembrolizumab | 7.2 | true | MSS | 2026-03-15T05:36:00.957408+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_316946 | REC_0014887 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 24 | 4.2 | 59 | female | 1 | 15 | 7.6 | 3 | alectinib 600 mg BID | 20.7 | true | MSS | 2026-03-15T05:36:00.957777+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_785981 | REC_0014888 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 31 | 12.4 | 78 | female | 1 | 20 | 3 | 3 | sotorasib 960 mg daily | 29.9 | true | MSI-H | 2026-03-15T05:36:00.958112+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_150631 | REC_0014889 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 30 | 13.2 | 53 | female | 0 | 23 | 5.1 | 3 | pembrolizumab 200 mg q3w | 11.2 | true | MSI-H | 2026-03-15T05:36:00.958465+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_356723 | REC_0014890 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 27 | 19.4 | 68 | female | 0 | 23 | 4.3 | 2 | osimertinib 80 mg daily | 15.7 | false | MSS | 2026-03-15T05:36:00.958809+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_978568 | REC_0014891 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 23 | 8.2 | 53 | female | 0 | 13 | 5.3 | 7 | pembrolizumab 200 mg q3w | 15.3 | true | MSS | 2026-03-15T05:36:00.959150+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_462188 | REC_0014892 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 12 | 12.9 | 40 | female | 0 | 13 | 3.7 | 7 | entrectinib 600 mg daily | 10.9 | false | MSS | 2026-03-15T05:36:00.959511+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_391675 | REC_0014893 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 30 | 21.1 | 87 | female | 0 | 11 | 6.6 | 8 | alectinib 600 mg BID | 13.1 | false | MSI-H | 2026-03-15T05:36:00.959862+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_586278 | REC_0014894 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 16 | 6.7 | 58 | male | 1 | 28 | 4.6 | 3 | pembrolizumab 200 mg q3w | 4.9 | false | MSS | 2026-03-15T05:36:00.960269+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_805140 | REC_0014895 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 25 | 6.8 | 62 | female | 1 | 49 | 5.1 | 2 | carboplatin + paclitaxel + pembrolizumab | 16.4 | false | MSS | 2026-03-15T05:36:00.960647+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_877200 | REC_0014896 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 20 | 12.9 | 65 | female | 0 | 17 | 5.1 | 6 | osimertinib 80 mg daily | 9.7 | true | MSS | 2026-03-15T05:36:00.960987+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_585305 | REC_0014897 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 18 | 12.6 | 63 | female | 0 | 9 | 7 | 2 | entrectinib 600 mg daily | 18.7 | false | MSI-H | 2026-03-15T05:36:00.961361+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_865708 | REC_0014898 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 23 | 9.4 | 62 | male | 1 | 17 | 5.3 | 4 | pembrolizumab 200 mg q3w | 15.3 | true | MSS | 2026-03-15T05:36:00.961736+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_555136 | REC_0014899 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 29 | 5.2 | 80 | female | 3 | 23 | 7.1 | 6 | alectinib 600 mg BID | 15.7 | false | MSS | 2026-03-15T05:36:00.962266+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_476425 | REC_0014900 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 29 | 13.9 | 62 | female | 0 | 21 | 7.7 | 6 | entrectinib 600 mg daily | 8.8 | true | MSI-H | 2026-03-15T05:36:00.962706+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.